Patents by Inventor Catherine A. Schnabel
Catherine A. Schnabel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230287511Abstract: The disclosure provides methods for the use of gene expression measurements to classify or identify neuroendocrine cancer in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.Type: ApplicationFiled: December 8, 2022Publication date: September 14, 2023Inventors: Catherine A. SCHNABEL, Yi ZHANG, Mark G. ERLANDER
-
Publication number: 20230083179Abstract: Methods of determining risk of recurrence of a breast cancer of a subject are provided. Also provided are methods of predicting responsiveness to a therapy of a breast cancer of a subject. Additionally, methods of recommending treatment for a subject that has breast cancer are provided. Further provided are methods of treating a subject that has breast cancer. Systems for performing described methods are also provided.Type: ApplicationFiled: November 18, 2022Publication date: March 16, 2023Inventors: Yi Zhang, Catherine A. Schnabel
-
Patent number: 11549148Abstract: The disclosure provides methods for the use of gene expression measurements to classify or identify neuroendocrine cancer in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.Type: GrantFiled: July 21, 2017Date of Patent: January 10, 2023Assignee: BIOTHERANOSTICS, INC.Inventors: Catherine A. Schnabel, Yi Zhang, Mark G. Erlander
-
Patent number: 11530448Abstract: Methods of determining risk of recurrence of a breast cancer of a subject are provided. Also provided are methods of predicting responsiveness to a therapy of a breast cancer of a subject. Additionally, methods of recommending treatment for a subject that has breast cancer are provided. Further provided are methods of treating a subject that has breast cancer. Systems for performing described methods are also provided.Type: GrantFiled: November 11, 2016Date of Patent: December 20, 2022Assignee: BIOTHERANOSTICS, INC.Inventors: Yi Zhang, Catherine A. Schnabel
-
Publication number: 20220186317Abstract: Provided are methods of determining risk of cancer recurrence in a subject afflicted with breast cancer. Also provided are methods of determining responsiveness to treatment of a subject afflicted with breast cancer. Additionally provided are methods of treating a subject afflicted with breast cancer.Type: ApplicationFiled: October 28, 2021Publication date: June 16, 2022Inventors: Catherine A. Schnabel, Dennis C. Sgroi, Yi Zhang, Brock Schroeder, Mark G. Erlander
-
Publication number: 20210355550Abstract: The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.Type: ApplicationFiled: July 27, 2021Publication date: November 18, 2021Inventors: Dennis SGROI, Mark G. ERLANDER, Yi ZHANG, Catherine A. SCHNABEL
-
Patent number: 11078538Abstract: The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.Type: GrantFiled: October 19, 2016Date of Patent: August 3, 2021Assignee: Biotheranostics, Inc.Inventors: Dennis Sgroi, Mark G. Erlander, Yi Zhang, Catherine A. Schnabel
-
Patent number: 10253369Abstract: Provided are methods of determining whether a subject having ER+ breast cancer is expected to benefit from treatment with combination endocrine therapy and mTOR inhibitor therapy. Also provided are methods of treating a subject having ER+ breast cancer.Type: GrantFiled: May 28, 2015Date of Patent: April 9, 2019Assignee: BIOTHERANOSTICS, INC.Inventors: Catherine Schnabel, Yi Zhang, Mark G. Erlander
-
Publication number: 20180135131Abstract: The disclosure provides methods for the use of gene expression measurements to classify or identify neuroendocrine cancer in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.Type: ApplicationFiled: July 21, 2017Publication date: May 17, 2018Inventors: Catherine A. SCHNABEL, Yi ZHANG, Mark G. ERLANDER
-
Publication number: 20170253931Abstract: The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.Type: ApplicationFiled: October 19, 2016Publication date: September 7, 2017Inventors: Dennis SGROI, Mark G. ERLANDER, Yi ZHANG, Catherine A. SCHNABEL
-
Publication number: 20170137891Abstract: Methods of determining risk of recurrence of a breast cancer of a subject are provided. Also provided are methods of predicting responsiveness to a therapy of a breast cancer of a subject. Additionally, methods of recommending treatment for a subject that has breast cancer are provided. Further provided are methods of treating a subject that has breast cancer. Systems for performing described methods are also provided.Type: ApplicationFiled: November 11, 2016Publication date: May 18, 2017Inventors: Yi Zhang, Catherine A. Schnabel
-
Publication number: 20150344967Abstract: Provided are methods of determining whether a subject having ER+ breast cancer is expected to benefit from treatment with combination endocrine therapy and mTOR inhibitor therapy. Also provided are methods of treating a subject having ER+ breast cancer.Type: ApplicationFiled: May 28, 2015Publication date: December 3, 2015Applicant: BIOTHERANOSTICS, INCInventors: Catherine Schnabel, Yi Zhang, Mark G. Erlander
-
Publication number: 20150203921Abstract: Provided are methods of determining risk of cancer recurrence in a subject afflicted with breast cancer. Also provided are methods of determining responsiveness to treatment of a subject afflicted with breast cancer. Additionally provided are methods of treating a subject afflicted with breast cancer.Type: ApplicationFiled: September 10, 2014Publication date: July 23, 2015Inventors: Catherine A. Schnabel, Dennis C. Sgroi, Yi Zhang, Brock Schroeder, Mark G. Erlander
-
Publication number: 20140349856Abstract: The disclosure provides methods for the use of gene expression measurements to classify or identify neuroendocrine cancer in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.Type: ApplicationFiled: March 24, 2014Publication date: November 27, 2014Applicant: BIOTHERANOSTICS, INC.Inventors: Catherine A. Schnabel, Yi Zhang, Mark G. Erlander
-
Publication number: 20130281502Abstract: The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.Type: ApplicationFiled: June 10, 2013Publication date: October 24, 2013Applicants: GENERAL HOSPITAL CORPORATION, BIOTHERANOSTICS INC.Inventors: Dennis Sgroi, Mark G. Erlander, Yi Zhang, Catherine A. Schnabel
-
Publication number: 20040121307Abstract: A method for detecting cellular differentiation using Optophoretic analysis is provided. The method includes the steps of providing a plurality of cells, moving an optical gradient relative to the plurality of cells so as to cause displacement of at least some of the plurality of cells, measuring the travel distance of at least some of the plurality of cells, repeating the steps of moving the optical gradient and measuring the travel distance of at least some of the plurality of cells, and identifying those cells having changing travel distances. The method is able to detect the early onset of cellular differentiation. The method is also applicable to detecting and monitoring adipogenesis.Type: ApplicationFiled: December 19, 2002Publication date: June 24, 2004Applicant: Genoptix, IncInventors: Catherine A. Schnabel, Ilona A. Kariv, Thomas D.Y. Chung
-
Publication number: 20040033539Abstract: Optophoretic methods are used to determine one or more biological properties or changes in biological properties of one or more cells or cellular components. The methods use optical or photonic forces to select, identify, characterize, and/or sort whole cells or groups of cells. The methods are useful in a number of applications, including, but not limited to, drug screening applications, toxicity applications, protein expression applications, rapid clonal selection applications, biopharmaceutical monitoring and quality control applications, cell enrichment applications, viral detection, bacterial drug sensitivity screening, environmental testing, agricultural testing, food safety testing, personalized medicine applications as well as biohazard detection and analysis.Type: ApplicationFiled: April 29, 2003Publication date: February 19, 2004Applicant: Genoptix, IncInventors: Catherine A. Schnabel, Jonathan Diver, Ilona Kariv, Anita Forster, Elinore Mercer, Jeffrey M. Hall, Tina S. Nova
-
Publication number: 20030194755Abstract: A method for detecting the onset of apoptosis in cells using a moving optical gradient includes the steps of exposing at least a portion of the cells to at least one chemical compound, moving the cells and the optical gradient relative to each other so as to cause displacement of at least some of the cells, measuring the displacement of at least a portion of the displaced cells, comparing the measured displacement with the measured displacement of at least one control cell that has not been treated with the at least one chemical compound. The step of comparing the measured displacement of the control and tested cells determines the onset of apoptosis. Methods are also provided for monitoring cells throughout apoptosis.Type: ApplicationFiled: December 19, 2002Publication date: October 16, 2003Applicant: Genoptix, Inc.Inventors: Catherine A. Schnabel, Jeffrey M. Hall, Kristie L. Lykstad
-
Publication number: 20030124516Abstract: Optophoretic methods are used to determine one or more biological properties or changes in biological properties of one or more cells or cellular components. The methods use optical or photonic forces to select, identify, characterize, and/or sort whole cells or groups of cells. The methods are useful in a number of applications, including, but not limited to, drug screening applications, toxicity applications, protein expression applications, rapid clonal selection applications, biopharmaceutical monitoring and quality control applications, cell enrichment applications, viral detection, bacterial drug sensitivity screening, environmental testing, agricultural testing, food safety testing, as well as biohazard detection and analysis.Type: ApplicationFiled: September 12, 2002Publication date: July 3, 2003Applicant: Genoptix, Inc.Inventors: Thomas D. Y. Chung, Anita Forster, Jeff Hall, Ilona Kariv, Kris Lykstad, Catherine A. Schnabel, William Soo Hoo, Jonathan Diver